Legacy Technology Holdings, Inc. (LTHO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLegacy Technology Holdings, Inc. (LTHO) trades at $0.0003. Legacy Technology Holdings, Inc. is a healthcare company specializing in genomic preventative medicine and medical software. Their platform analyzes patient lifestyle and genetic data to provide personalized health insights. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for LTHO: LTHO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Legacy Technology Holdings, Inc. (LTHO) Healthcare & Pipeline Overview
Legacy Technology Holdings, Inc. develops and commercializes a web-based genomic preventative medicine and medical software solution. The company leverages algorithms to analyze patient lifestyle and genetic data, offering personalized health insights within the specialty and generic drug manufacturing sector. It faces competition in a rapidly evolving healthcare technology landscape.
What Is the Investment Thesis for LTHO?
Legacy Technology Holdings, Inc. operates in the high-growth personalized medicine market, leveraging genomic data and lifestyle factors to provide preventative healthcare solutions. However, with a market capitalization of $0.00B and a negative P/E ratio of -0.18, the company's financial stability is uncertain. Key value drivers include the expansion of its software platform and the acquisition of new customers. Growth catalysts include increasing adoption of personalized medicine and strategic partnerships with healthcare providers. Potential risks include intense competition, regulatory hurdles, and the need for continuous innovation to maintain a competitive edge. Investors should closely monitor the company's ability to achieve profitability and secure funding for future growth.
Based on FMP financials and quantitative analysis
LTHO Key Highlights
Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- P/E Ratio of -0.18 suggests the company is currently unprofitable, requiring further investigation into its financial performance.
- Beta of -5.84 indicates a high degree of volatility and a negative correlation with the market, potentially making it a risky investment.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than distributing profits to shareholders.
- Focus on genomic preventative medicine aligns with the growing trend of personalized healthcare, presenting a significant market opportunity.
Who Are LTHO's Competitors?
LTHO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $13.0M | — |
| COSM COSM | $0.35 | -9.03% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.01 | -1.95% | $24.0M | — |
| CPHI CPHI | $0.65 | -0.61% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LTHO's Key Strengths?
Proprietary algorithms for genomic and lifestyle data analysis.
- Focus on personalized preventative medicine.
- Web-based software platform for accessibility.
- Potential for strategic partnerships with healthcare providers.
What Are LTHO's Weaknesses?
Limited market capitalization of $0.00B.
- Negative P/E ratio indicating unprofitability.
- High beta suggesting significant volatility.
- Dependence on continuous innovation to maintain competitive edge.
What Are the Key Risks for LTHO?
Intense competition from established pharmaceutical companies and emerging healthcare technology providers.
- Regulatory hurdles and compliance requirements for genomic testing and medical software.
- Data privacy and security breaches compromising patient information.
- Limited financial resources and potential need for additional funding.
- Dependence on key personnel and potential loss of expertise.
What Are LTHO's Competitive Advantages?
- Proprietary algorithms for analyzing genomic and lifestyle data.
- Web-based software platform for easy accessibility.
- Focus on personalized preventative medicine.
- Potential for network effects as more data is collected and analyzed.
What Does LTHO Do?
Legacy Technology Holdings, Inc., incorporated in 2012 and based in Arvada, Colorado, operates within the healthcare sector, focusing on the development and commercialization of a web-based genomic preventative medicine and medical software solution. The company's core offering is a platform that utilizes proprietary algorithms to analyze a comprehensive range of individual patient lifestyle factors. This includes data derived from blood tests, biometrics, dietary habits, environmental exposures, nutraceutical and pharmaceutical usage, and genetic markers. By integrating these diverse data streams, Legacy Technology Holdings aims to provide personalized health insights and recommendations to individuals and healthcare providers. The company's software solution is designed to assist in the early detection and prevention of diseases by identifying potential health risks based on an individual's unique genomic and lifestyle profile. Legacy Technology Holdings targets the growing market for personalized medicine, where healthcare decisions are increasingly tailored to individual patient characteristics. The company's business model centers around the licensing and subscription of its software platform to healthcare providers and potentially directly to consumers. The company aims to establish itself as a key player in the evolving landscape of preventative and personalized healthcare solutions.
What Products and Services Does LTHO Offer?
- Develops web-based genomic preventative medicine software.
- Commercializes medical software solutions.
- Uses algorithms to analyze patient lifestyle data.
- Analyzes blood tests and biometric data.
- Incorporates diet and environmental factors into health assessments.
- Integrates nutraceutical and pharmaceutical data.
- Analyzes genetic markers to identify health risks.
How Does LTHO Make Money?
- Licenses its software platform to healthcare providers.
- Offers subscription-based access to its genomic analysis tools.
- Potentially generates revenue through direct-to-consumer genetic testing services.
What Industry Does LTHO Operate In?
Legacy Technology Holdings, Inc. operates within the rapidly evolving drug manufacturers - specialty & generic industry, which is experiencing a shift towards personalized medicine and preventative healthcare solutions. The market is characterized by increasing demand for tailored treatments based on individual patient characteristics. The competitive landscape includes established pharmaceutical companies, biotechnology firms, and emerging healthcare technology providers. Legacy Technology Holdings aims to differentiate itself through its web-based genomic preventative medicine platform. The company faces competition from firms such as Aravive, Inc. (AREVF), Conatus Pharmaceuticals Inc. (CNNXF), Conformis, Inc. (CSTF), Global Health Partner AB (GBHPF), and Grove, Inc. (GRVE).
Who Are LTHO's Key Customers?
- Healthcare providers seeking personalized medicine solutions.
- Hospitals and clinics looking to improve preventative care.
- Individuals interested in proactive health management.
- Wellness centers and health coaches.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Legacy Technology Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Arvada, US. The company is led by CEO Redgie T. Green. LTHO has traded publicly since 2006.
Key Financial Metrics
Return on equity for Legacy Technology Holdings, Inc. stands at 45.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
LTHO Financials
LTHO Latest News
No recent news available for LTHO.
LTHO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LTHO.
Price Targets
Wall Street price target analysis for LTHO.
LTHO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LTHO; grades run from A+ (80-100) to F (below 30).
LTHO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Legacy Technology Holdings, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information availability and increased volatility.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for higher price volatility due to lower trading volume.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable information about the company.
- Lower regulatory oversight compared to major exchanges.
- Verify the company's registration and legal standing.
- Assess the company's financial condition and ability to continue as a going concern.
- Research the background and experience of the company's management team.
- Review any available financial statements and disclosures.
- Understand the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk management practices.
- Consult with a qualified financial advisor before investing.
- Company incorporated in 2012 suggests some operating history.
- Based in Arvada, Colorado, providing a physical location.
- Focus on genomic preventative medicine aligns with current healthcare trends.
- Development of a web-based software platform indicates technological capabilities.
What Investors Ask About Legacy Technology Holdings, Inc. (LTHO) — Healthcare
What does Legacy Technology Holdings, Inc. do?
Legacy Technology Holdings, Inc. develops and commercializes a web-based genomic preventative medicine and medical software solution. The company uses algorithms to analyze data on individual patient lifestyle factors, such as blood tests, biometrics, diet, environmental, nutraceutical, pharmaceutical, and genetic makers.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available for Legacy Technology Holdings, Inc.